

S4 Table. Company size measured in net sales and number of employees

| NCE | Product name | MA year | Originator | USD million | Employees | Developed and marketed by | USD millions | Employees | Total number of countries entered |
|-------------------------------|--------------|---------|------------------------|-------------|-----------|------------------------------------|--------------------------------------|---------------------------------|-----------------------------------|
| moxifloxacin | Avelox® | 1999 | Bayer | 7444.97 | 120400 | Bayer | 7639.93 | 120400 | 75 |
| linezolid | Zyvox® | 2000 | Pharmacia | 9314.00 | 44300 | Pharmacia | 13837.00 | no data | 70 |
| ertapenem | Invanz® | 2002 | Astra Zeneca | 17841.00 | 15000 | Merck | 19946.20 | 77300 | 65 |
| tigecycline | Tygacil® | 2005 | Wyeth | 17875.00 | 49732 | Wyeth | 17875.00 | 49732 (2005) | 65 |
| daptomycin | Cubicin® | 2003 | Eli Lilly | 11855.90 | 46100 | Cubist | 3.716 | 290 | 47 |
| doripenem | Finibax® | 2005 | Shionogi | 1531.35 | 4293 | Shinogi/ Peninsula (owned by J&J) | 22322.00 (J&J) | 115600 (J&J) | 44 |
| telithromycin | Ketek® | 2001 | Aventis | 15726.35 | no data | Aventis | 16138.19 | no data | 43 |
| ceftaroline | Teflaro® | 2010 | Takeda | 17212.25 | 19654 | Forest Laboratories Inc. | 3903.52 | 5000 | 31 |
| gatifloxacin | Tequin® | 1999 | Kyorin Pharmaceuticals | 379.43 | 1000 | Bristol-Myers Squibb | 16000.00 | 54500 | 30 |
| gemifloxacin | Factive® | 2003 | LG Life Sciences | 6813.65 | no data | Oscient | 6.612 | 94 | 28 |
| dalfopristin/ quinupristin | Synercid® | 1999 | Rhone-Poulenc-Rorer | 4677.78 | 65180 | Aventis | 4456.86 | 65180 | 21 |
| prulifloxacin | Sword® | 2002 | Nippon Shinyaku | 342.15 | 1800 | Nippon Shinyaku and Meiji Seika | 903.96 | 4418 (Meiji) | 14 |
| ceftobiprole | Zeftera® | 2008 | Roche | 18309.66 | 54141 | Basilea/ J&J | 9.91 (Basilea) 24567.00 (pharma J&J) | 300 (Basilea) 118700 (J&J) | 5 |
| balofloxacin | Q-roxin® | 2002 | Chugai Pharmaceutical | 1900.73 | 6282 | Choongwae (now JW Pharmaceuticals) | 345.07 | no data | 3 |
| biapenem | Omegacin® | 2002 | Wyeth KK (Wyeth) | 14584.04 | 52762 | Meiji Seika | 903.96 | 4418 | 3 |
| pazufloxacin | Pasil® | 2002 | Toyama Chemical | 0.2315 | 1662 | Toyama Chemical/Mitsubishi | 1869.98 | 5339 (Mitsubishi) | 3 |
| garenoxacin | Geninax® | 2007 | Toyama Chemical | 0.15 | 1025 | Toyama /Taisho/Astellas | 836.23 (Taisho) 8314.86 (Astellas) | 5327 (Taisho) 13 900 (Astellas) | 2 |
| sitafoxacin | Gracevit® | 2008 | Daiichi Sankyo | 8929.42 | 28895 | DaiichiSankyo | 7972.26 | 28895 | 2 |
| tedizolid | Sivextro® | 2014 | Dong-A Pharmaceutical | 401.64 | 2563 | Cubist | 1054.44 | 873 | 2 |

| | | | | | | | | | |
|------------------------|-----------|------|--------------------------------------|----------|----------|-------------------------------|----------|------------------|---|
| antofloxacin | 优朋® | 2010 | Shanghai Institute Of Materia Medica | academia | academia | Anhui global pharmaceutical | academia | academia | 1 |
| ceftolozane/tazobactam | Zerbaxa® | 2014 | Astellas | 9836.04 | 17649 | Cubist | 1054.44 | 873 | 1 |
| dalbavancin | Dalvance® | 2014 | Vicuron Pharmaceuticals | 8.372 | no data | Durata (spin off from Pfizer) | 0.00 | 68 (Durata) | 1 |
| oritavancin | Nuvocid® | 2014 | Eli Lilly | 17269.00 | 39135 | The Medicines Company | 724.40 | 727 | 1 |
| tebipenem | Orapenem® | 2009 | Wyeth K.K (Wyeth) | 19025.4 | no data | Meiji Seika Pharma | 1468.38 | 14168 | 1 |
| telavancin | Vibativ® | 2009 | Theravance | 24.37 | 194 | Theravance/Astellas | 11110.55 | 15161 (Astellas) | 1 |

Net sales in USD (in millions) and number of employees the year of market entry, of the companies in charge of development and marketing of the NCEs.